APOE4 Study Links Wnt Signaling to Disrupted Brain Insulation

Executive Summary

• A study led by Picower Institute neuroscientists at MIT reports that the APOE4 gene variant suppresses Wnt signaling in oligodendrocytes, lowering myelination and increasing lipid droplets. Source
• The researchers used a genome-wide CRISPR screen and chromatin accessibility analysis, reporting what the release calls a striking overlap in results pointing to Wnt dysregulation. Source
• Restoring Wnt signaling through GSK3b inhibition improved myelination in human cell cultures, organoids and APOE4 mice, which the release describes as a proof-of-concept fix. Source

Key Takeaways

• The paper, titled Genome-wide CRISPR screen reveals Wnt signaling as a potential therapeutic target for lipid accumulation and impaired myelination in APOE4 oligodendrocytes, was published Oct. 15 in Cell Stem Cell, according to the MIT release dated Oct. 28.
• Wnt signaling deficiency was associated with lipid droplet accumulation instead of use of fats for myelination of axon branches, per the source.
• In APOE4 oligodendrocytes, beta-catenin expression was reduced and GSK3b expression was excessive relative to APOE3 cells, the researchers report.
• The study was led by Picower Professor Li-Huei Tsai and lead author Leyla Akay PhD '25; Akay and Tsai have applied for a patent on the CRISPR screen results, the release states.

MIT Study Scope and Preclinical Limits

The MIT release describes several lines of evidence linking APOE4 to suppressed Wnt signaling in oligodendrocytes, the cells that wrap neurons in the fatty sheath called myelin. The work combined a genome-wide CRISPR screen in cultures of human APOE4-carrying oligodendrocytes with analysis of chromatin accessibility in human oligodendrocyte cultures and postmortem human brain samples, comparing APOE4 to APOE3 samples in each case, according to the source. The release quotes Tsai describing a striking overlap between the CRISPR and ATAC-seq results, both pointing to Wnt pathway dysregulation.Importantly, the intervention results reported are preclinical. The source describes human cell cultures, organoid cultures combining APOE4 oligodendrocytes with neurons, and mice genetically modeling Alzheimer's tau pathology. It does not report human trials, dosing in people or any clinical outcome. Readers should treat the described restoration of myelination as a laboratory proof of concept, not an established human therapy.

MIT Molecular Findings: Wnt, Beta-Catenin and GSK3b

According to the release, further analysis showed how Wnt signaling became depressed in cultured APOE4 oligodendrocytes. Two proteins compete to regulate Wnt: beta-catenin promotes it and GSK3b suppresses it. The team found reduced beta-catenin expression and excessive GSK3b expression in APOE4 oligodendrocytes compared with APOE3 ones, per the source. The researchers then tested chemical manipulations of GSK3b activity. In human APOE3 oligodendrocyte cultures, increasing GSK3b with Dif3 increased lipid droplets; in APOE4 oligodendrocytes, inhibiting GSK3b with CHIR99021 reduced droplets, the release states. In organoid cultures, inhibiting GSK3b increased myelination and promoted growth of neural axons. In APOE4 mice modeling tau pathology, CHIR99021 treatment was associated with reduced lipid droplets and increased myelination in the hippocampus compared with untreated controls.

MIT Signals Table

MIT Implementation Risks

The source frames GSK3b inhibition as a proof-of-concept therapeutic strategy rather than a validated treatment. Any practical translation faces the gap between cultured cells, organoids and mouse models and human biology, a limit the release does not claim to have crossed. The study also reports a patent application by Akay and Tsai on the CRISPR screen results, a commercial and intellectual-property consideration the source discloses without further detail. Our editorial recommendation is that readers track peer-reviewed follow-up and avoid treating chemical GSK3b inhibition results in animals as evidence of human efficacy. The release notes the authors are interested in investigating GSK3b's linkage to tau phosphorylation, a major feature of Alzheimer's pathology, indicating open mechanistic questions remain. Funding came from the National Institutes of Health, the Robert and Renee E. Belfer Family Foundation, the Manthripragada McManama Alzheimer's Fund, the CAMA Seed Fund, the J. Crayton Pruitt Foundation, Joseph P. DiSabato and Nancy Sakamoto, and the Freedom Together Foundation, per the source.

MIT Research Methods and Data Availability

The release states that raw data from the study is available on the Open Science Framework. It lists the full author group and identifies the paper title. Our editorial recommendation is that analysts examining the findings consult the underlying publication and raw data rather than relying on the press summary alone; this is our judgment, not a measured result. The source also links to a check for open access versions of the research.

What This Means for Practitioners

For researchers and drug-development professionals, the MIT release offers a mechanistic hypothesis worth monitoring: that APOE4 suppresses Wnt signaling in oligodendrocytes, shifting lipid handling toward droplet accumulation and away from myelination, with GSK3b inhibition tested as a laboratory intervention. The evidence base described consists of human cell cultures, organoid cultures and APOE4 mouse models, so practitioners should not infer human safety, dosing or efficacy. Our editorial recommendation is to treat the findings as a preclinical target-validation signal and to await peer-reviewed replication and clinical data before drawing commercial or therapeutic conclusions. The disclosed patent application and the authors' stated interest in GSK3b's link to tau phosphorylation are relevant context for anyone tracking the program.

Editorial Independence and Source Note

Our recommendations reflect editorial judgment only and are not independent product testing or verification. This article is based solely on the supplied MIT News publisher page: MIT News release on APOE4 and Wnt signaling. Related reading, not used as source evidence: Related Genomics coverage, Related Genomics coverage, Related Genomics coverage.